TABLE 4.
Reported characteristics associated with eight antibody-drug conjugates (ADCs) from the first quarter of 2004 to the third quarter of 2023.
| Characteristics | Antibody-drug conjugate |
|---|---|
| Number of events | 1,863 |
| Age group, n (%) | |
| <18 years | 52 (2.79) |
| 18–65 years | 586 (31.45) |
| ≥65 years | 613 (32.90) |
| Unknown | 612 (32.85) |
| Patient’s gender, n (%) | |
| Male | 752 (40.37) |
| Female | 834 (44.77) |
| Unknown | 277 (14.87) |
| Reported countries, n (%) | |
| United States | 563 (30.22) |
| Japan | 449 (24.10) |
| France | 97 (5.21) |
| Germany | 89 (4.78) |
| Canada | 59 (3.17) |
| Others countries | 488 (26.19) |
| Unknown | 118 (6.33) |
| Reported year, n (%) | |
| 2004 | 85 (4.56) |
| 2005 | 105 (5.64) |
| 2006 | 147 (7.89) |
| 2007 | 77 (4.13) |
| 2008 | 69 (3.70) |
| 2009 | 66 (3.54) |
| 2010 | 27 (1.45) |
| 2011 | 88 (4.72) |
| 2012 | 31 (1.66) |
| 2013 | 24 (1.29) |
| 2014 | 41 (2.20) |
| 2015 | 22 (1.18) |
| 2016 | 24 (1.29) |
| 2017 | 27 (1.45) |
| 2018 | 82 (4.40) |
| 2019 | 114 (6.12) |
| 2020 | 63 (3.38) |
| 2021 | 181 (9.72) |
| 2022 | 369 (19.81) |
| 2023 | 223 (11.97) |
| Outcome of adverse events, n (%) | |
| Death | 770 (41.33) |
| Hospitalization initial or prolonged | 407 (21.85) |
| Life-threatening | 187 (10.04) |
| Disability | 9 (0.48) |
| Required intervention to prevent permanent impairment | 8 (0.43) |
| Other | 431 (23.13) |
| Unknown | 51 (2.74) |